Â鶹ŮÓÅ

The Trump administration has a message for the biggest names in health care and tech: You won’t control the development of artificial intelligence in medicine. Top officials at the Department of Health and Human Services tell POLITICO that the administration does not support a multi-year quasi-regulatory effort by firms including Microsoft and OpenAI, and health systems including the Mayo Clinic and Duke Health, to pilot private-sector-led vetting of AI tools under the banner of the Coalition for Health AI. (Reader, 10/1)

When UpToDate, the decades-old, expert-curated medical resource for doctors, announced the launch of a generative artificial intelligence update last week, clinicians responded with a common refrain: It’s about time. (Palmer, 10/2)

The FDA approved oral remibrutinib (Rhapsido) as a second-line treatment for chronic spontaneous urticaria (CSU), or chronic hives, Novartis announced on Tuesday. Indicated for adults with stubborn symptoms despite the use of antihistamines, the approval marks the first Bruton's tyrosine kinase (BTK) inhibitor for CSU. (Ingram, 10/1)

Today, Morbidity and Mortality Weekly Report published updated guidance from the US Centers for Disease Control and Prevention (CDC) on postexposure prophylaxis (prevention) and treatment of the rare but potentially serious tickborne disease tularemia. The recommendations are aimed at healthcare providers caring for patients with naturally occurring infections or, in the case of bioterrorist deployment of the pathogen, working with preparedness experts and public health authorities to prepare their clinics, hospitals, and communities. (Van Beusekom, 10/1)

Despite ongoing concern over antibiotic resistance, a new report finds there are fewer antibacterial medicines in clinical pipelines than just two years ago and relatively few qualify as innovative, suggesting the majority of treatments would be insufficient to tackle the fast-growing public health threat. (Silverman, 10/2)

Valneva today reported strong antibody persistence for Ixchiq, its live-attenuated vaccine against chikungunya, a virus spread by mosquitoes. In a press release, the company said data from 254 healthy adults suggested that 95% retained an antibody response above the seroresponse threshold for 4 years after a single dose. Antibody persistence in adults age 65 and older was similar to that for younger adults, which held for geometric mean titers and seroresponse rates. (Schnirring, 10/1)

Providers are eyeing remote scanning technology as a way to address the imbalance between too many requests for imaging tests and too few technologists to handle them. A handful of medtech companies received Food and Drug Administration clearance in the past two years for products that allow technologists to perform multiple scans simultaneously from remote locations. (Dubinsky, 10/1)

Researchers have found that patients with amyotrophic lateral sclerosis have autoimmune responses, a finding with the potential to reshape how scientists think of the devastating and complex neurologic disorder. (Wosen, 10/1)

As he manages his own amyotrophic lateral sclerosis, actor Eric Dane is also advocating for the continuation of the Accelerating Access to Critical Therapies for ALS Act, which is set to expire in 2026. The actor, along with the nonprofit organization I AM ALS, spoke with U.S. Rep. Eric Swalwell (D-Dublin) on Tuesday about the importance of the legislation, which provides funding for research and gives patients early access to treatments. (Solorzano, 10/1)